MorphoSys (NASDAQ:MOR) Stock Rating Reaffirmed by Leerink Partnrs

Leerink Partnrs reiterated their market perform rating on shares of MorphoSys (NASDAQ:MOR – Free Report) in a research note published on Wednesday morning, PriceTargets.com reports. Leerink Partnrs also issued estimates for MorphoSys’ FY2026 earnings at ($0.78) EPS. A number of other research analysts have also recently weighed in on MOR. Morgan Stanley raised MorphoSys from […]

Related Keywords

United States ,Leerink Partnrs ,Morgan Stanley ,Blackrock Inc ,Virtu Financial ,Qube Research Technologies Ltd ,Jpmorgan Chase Co ,Goldman Sachs Group ,Free Report ,Get Free Report ,Technologies Ltd ,Morphosys Daily ,Morphosys ,Nasdaq Mor ,Humor ,Medical ,Reiterated Rating ,